In this exclusive interview, Jess Fertig hosts James McDonnell, CEO of Prescient Therapeutics (ASX: PTX), a biotech innovator in the healthcare sector. Discover how PTX's lead asset, PTX 100, is advancing through crucial Phase 2 trials targeting cutaneous T cell lymphoma (CTCL), with promising response rates and minimal serious adverse events. James shares insights into the company's strategic pathway, including FDA fast track designation and potential market opportunities exceeding $1.8 billion. Learn how PTX's targeted Ras pathway disruption could unlock new treatments for multiple cancers like lung, pancreatic, and biliary tumours. The conversation also covers funding strategies, the impact of government R&D incentives, and upcoming milestones that could accelerate PTX’s journey to market. Whether you're an early stage biotech investor or interested in innovative cancer therapies, this interview provides valuable insights into PTX’s potential to revolutionise oncology care. Watch till the end for key investment highlights and why Prescient Therapeutics should be on your watchlist. 

📅 Timestamps:
0:02 Introduction
1:07 PTX Overview & Focus
3:14 PTX 100 Results & Safety
4:38 FDA Fast Track & Market Access
8:02 Market Opportunity & Future Potential
10:04 Development & Funding
14:03 Investment Highlights

🚨 Disclaimer: This content is for informational purposes only and does not constitute financial advice. Please conduct your own research before investing.

📌 Articles:
https://smallcaps.com.au/prescient-therapeutics-ptx-100-phase-2a-trials-outstanding-results/
https://smallcaps.com.au/prescient-therapeutics-fast-track-fda-ptx-100-t-cell-lymphoma/

🔎 More on Prescient Therapeutics:
https://smallcaps.com.au/stocks/asx-ptx/

See omnystudio.com/listener for privacy information.